a Sanofi company, announced today that in support of International Rare
Disease Day, the company is hosting several events internationally to
help raise awareness of rare diseases as a critical global health issue
requiring ongoing research, education and new...
a Sanofi company, today announced the publication of results from the
ENGAGE registration study evaluating Cerdelga® (eliglustat) in
treatment-naïve patients with Gaucher disease type 1 in the February 17,
of The Journal of the American Medical...
a Sanofi company, today presented data from its Phase 1b clinical study
at the Lysosomal Disease Network’s WORLD Symposium 2015 in Orlando, Fla.
detailing the investigational use of enzyme replacement therapy in the
non-neurological manifestations of acid...
a Sanofi company, today reported extension study data from its Phase 3
ENGAGE and ENCORE studies of Cerdelga® (eliglustat), a
first-line oral therapy approved by the FDA and the European Commission
for the treatment of certain adults with Gaucher disease type 1....